Antifolate Drugs In Cancer Therapy at CIOC 2027

Antifolate drugs represent a cornerstone in cancer therapy due to their ability to disrupt DNA synthesis, vital for rapidly dividing cancer cells. These drugs, including methotrexate and pemetrexed, inhibit folate metabolism, crucial for nucleotide synthesis, impeding cancer cell proliferation. By targeting folate-dependent enzymes like dihydrofolate reductase and thymidylate synthase, antifolates disrupt the production of DNA building blocks, inducing cell death in tumors. However, their efficacy can be compromised by resistance mechanisms and systemic toxicity. Ongoing research focuses on combination therapies to enhance efficacy and minimize adverse effects. Additionally, novel drug delivery systems aim to improve tumor targeting, maximizing antifolate benefits while minimizing off-target effects. Through innovative approaches, antifolate drugs continue to hold promise in advancing cancer treatment strategies.